|Bid||15.85 x 3200|
|Ask||19.50 x 1000|
|Day's Range||16.44 - 16.79|
|52 Week Range||13.53 - 19.84|
|Beta (3Y Monthly)||0.30|
|PE Ratio (TTM)||27.62|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||0.50 (3.04%)|
|1y Target Est||17.00|
CINCINNATI, Feb. 07, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to.
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
VIVO Cannabis and Trulieve Posted Strong Performance Last WeekCannabis sector performanceLast week cannabis stocks performed well due to strength in the broader equity market with the S&P 500 Index rising by 1.6%. From January 25 to February 1,
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 11.11% and -0.04%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cincinnati-based company said it had profit of 19 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The results surpassed Wall Street expectations. The average estimate ...
CINCINNATI, Jan. 24, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019.
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Meridian Bioscience, Inc. (NASDAQ:VIVO) due to its excellent fundamentals in more Read More...
Ericsson (ERIC) is likely to report higher year-over-year revenues in the fourth quarter of 2018 on the back of healthy growth dynamics.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in the first quarter of 2018. The year-over-year decline of approximately 2% is being driven by weakness in the Diagnostics segment. The Life Science segment is expected to post revenue about in line with first quarter 2018. To participate in the live call by telephone from the U.S., dial (866) 443-5802, or from outside the U.S., dial (513) 360-6924, and enter the audience pass code 5086695.
Meridian Bioscience, Inc. (VIVO) today announced that it has received FDA clearance for its new Alethia™ CMV Molecular Amplification Test (formerly, the illumigene brand). This assay is designed to specifically detect congenital Cytomegalovirus (cCMV) infection in newborns from an easy-to-collect saliva sample. Alethia CMV is the first qualitative test in a molecular amplification format, FDA-cleared for cCMV testing in newborns.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
The U.S. Food and Drug Administration approved on Friday the first test - a diagnostic from Meridian Bioscience Inc - to help detect a type of herpes virus in newborns. Meridian's Alethia CMV Assay Test System detects cytomegalovirus (CMV) DNA from saliva swabs and won approval for use in babies younger than 21 days of age infected during pregnancy. Over half of adults have been infected with CMV by the age of 40, according to the Centers for Disease Control and Prevention.
Meridian Bioscience Inc is an integrated life science company. The dividend yield of Meridian Bioscience Inc stocks is 2.69%. Meridian Bioscience Inc had annual average EBITDA growth of 2.00% over the past ten years.
MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations in the fiscal year ended June 30.
Investors who want to cash in on Meridian Bioscience Inc’s (NASDAQ:VIVO) upcoming dividend of US$0.13 per share have only 2 days left to buy the shares before its ex-dividend date, Read More...
In September 2018, Meridian Bioscience Inc (NASDAQ:VIVO) announced its most recent earnings update, which suggested that the business gained from a robust tailwind, eventuating to a double-digit earnings growth of Read More...
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 25.00% and 3.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cincinnati-based company said it had profit of 13 cents. Earnings, adjusted for one-time gains and costs, came to 20 cents per share. The results beat Wall Street expectations. ...